lunes, 21 de agosto de 2017

Childhood Liver Cancer Treatment (PDQ®)—Health Professional Version - National Cancer Institute

Childhood Liver Cancer Treatment (PDQ®)—Health Professional Version - National Cancer Institute
National Cancer Institute

Childhood Liver Cancer Treatment (PDQ®)–Health Professional Version


SECTIONS


Changes to This Summary (08/10/2017)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Revised text to state that the finding of an alpha-fetoprotein level of 100 to 1,000 ng/mL was significant only among patients younger than 8 years in the backbone PRETEXT III group.
Added text about the APEC1621 (NCT03155620) trial as a treatment option under clinical evaluation.
This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
  • Updated: August 10, 2017

No hay comentarios:

Publicar un comentario